BNET Industries
- Public
- US
Dow Jones Description
Advanced Biotherapy, Inc. is a corporation organized and existing under the laws of the State of Delaware, headquartered in Woodland Hills, California with laboratories in Columbia, Maryland. The Company has demonstrated the effectiveness of its pioneering scientific strategy in the use of therapeutic antibodies by conducting investigational clinical trials treating patients suffering from AIDS, multiple sclerosis, rheumatoid arthritis, corneal transplant rejection, uveitis and certain autoimmune skin conditions, including psoriasis, and alopecia, all Th1 mediated autoimmune diseases which appear to have the same proinflammatory Th-1 activity. To date, our activities have consisted primarily of research, development and non-United States investigational human clinical trials. Such activities have resulted in accumulated losses at December 31, 2004. Our Company is developing a biologic therapeutic approach for treating a range of autoimmune diseases based on an anti-cytokine platform technology.
Contact Information
227 West Monroe
Suite 3900
Chicago, Illinois 60606
312-701-0793
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
advanced biotherapy inc. and company - All News and Analysis
Advanced Biotherapy Inc. Receives ``Notice of Allowance'' from Patent Office for Use of Antibodies to Treat Uveitis
LOS ANGELES -- Company Expands Antibody Patent Portfolio for Treatment of Eye Disease and Plans to Develop Franchise for Treatment of Ocular Diseases Advanced Biotherapy, Inc. (OTCBB:ADVB), dedicated to pioneering the development and use of therapeutic antibodies, announced that the Company has received a "Notice of Allowance" from the...
Advanced Biotherapy Inc. Broadens Its Patent Estate
Business Editors/Health & Medical Writers LOS ANGELES--BUSINESS WIRE--March 18, 2003 Advanced Biotherapy Inc. (OTCBB:ADVB) was notified by the United States Patent and Trademark Office USPTO that it has been issued U.S. Patent No. 6,534,059 for the use of antibody to gamma interferon to treat corneal transplant rejection. The...
Advanced Biotherapy Inc. Receives `Notice of Allowance' From United States Patent and Trademark Office for Use of Antibodies to Gamma Interferon to Treat Corneal Transplant Rejection
Business Editors & Health/Medical Writers LOS ANGELES--BUSINESS WIRE--Dec. 2, 2002 Advanced Biotherapy Inc. (OTCBB:ADVB) has received a "Notice of Allowance" from the United States Patent and Trademark Office USPTO for a utility patent for the use of any form of antibody to gamma interferon to treat corneal transplant...
Advanced Biotherapy, Inc. Discloses Use Patent for Antibodies to Interferon-Gamma in the Treatment of Five Autoimmune Diseases
Business Editors, Health/Medical Writers WOODLAND HILLS, Calif.--BW HealthWire--Dec. 13, 2001 Advanced Biotherapy, Inc. (OTCBB: ADVB) announced today that antibodies to interferon-gamma (IFN-g) are now protected under U.S. patent law for use in five diseases of autoimmune etiology. The announcement of the assignment of this patent number coincides with...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Alexander L. Cappello | |
| Boris Skurkovich | |
| Edmond Buccellato | |
| John M Bendheim | |
| Joseph A Bellanti | |
| Lawrence Loomis | |
| Simon Skurkovich | |
| Thomas Pernice | |
| Richard P. Kiphart | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| David Valentine | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Cappello Capital Corp | Managing Director | Current |
| Inter-Tel, Incorporated | Current | |
| Advanced Biotherapy, Inc. | Current | |
| Biotherapy, Inc. | Chairman | Current |
| The Cheesecake Factory Incorporated | Board of Directors | Current |
| Cappello Capital Corp | Board of Directors | Current |
| CytRx Corporation | Former | |
| University of Southern California | B.S. Degree in finance (awarded the prestigious Order | Former |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current | |
| The University of Houston | undergraduate degree in Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current | |
| Cappello Capital Corp | Current | |
| Biotherapy, Inc. | Chairman | Current |
| Biotherapy, Inc. | Chief Executive Officer | Former |
| Biotherapy, Inc. | President | Former |
| University of Southern California | MBA degree with an emphasis in finance | Former |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current | |
| Cedars-Sinai Medical Center | Chairman | Former |
| University of Southern California | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| New Horizons Diagnostics Corporation | President | Current |
| Advanced Biotherapy, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Biotherapy, Inc. | Current | |
| Dole Food Company, Inc. | CEO | Former |
| Dole Food Company, Inc. | Vice President, Public Affairs | Former |
| University of Southern California | Bachelor of Arts degree | Former |
David W. Valentine has been one of our directors since May 2004. Mr. Valentine is currently the chief operating officer and a founding principal of Victory Park Capital, a private investment firm. Prior to co-founding Victory Park, Mr. Valentine served as the portfolio manager of Private Investments for a Chicago-based hedge fund as well as the Global Head Debt Private Placements for UBS Investment Bank. Prior to UBS, Mr. Valentine held several investment banking positions at ABNAMRO and Harris Nesbitt. Mr. Valentine also serves on the board of directors for Innovomed, Inc., Advanced Biotherapy, Inc. and Trustwave, Inc. He is also on the board of directors of a Washington DC-based advocacy group, the Friends of the Global Fight Against Aids, Tuberculosis, and Malaria. Mr. Valentine is the son-in-law of Richard Kiphart, our chairman.
| Organization | Position | Status |
|---|---|---|
| Victory Park | Founder | Current |
| Ambirontrustwave Limited | Board of Directors | Current |
| Lime Energy Co. | Board of Directors | Current |
| Advanced Biotherapy, Inc. | Board of Directors | Current |
| First Data Corporation | Former | |
| ABN AMRO Holding N.V. | Former | |
| Lime Energy Co. | Chair | Former |
| Harvard Business School | M.B.A. | Former |
| Dartmouth College | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| SAFLINK Corporation | Lead Independent Director | Current |
| William Blair Capital Partners | Head | Current |
| William Blair & Company LLC | Principal | Current |
| William Blair & Company, L.L.C. | Head of the Corporate Finance Department | Current |
| SAFLINK Corporation | Director Co-Chairman of the Board, Lead Independent Director | Current |
| Lime Energy Co. | Chairman | Current |
| Kapadia Energy Services | Chairman | Current |
| Maximum Performance Group | Chairman | Current |
| Emmi Solutions, LLC | Board of Directors | Current |
| Data, Inc. | Board of Directors | Current |
| Advanced Biotherapy, Inc. | Director | Current |
| Nature Vision, Inc. | Director | Current |
| SAFLINK Corporation | Director | Current |
| Lime Energy Co. | Board of Directors | Former |
| First Data Corporation | Director | Former |
| Harvard Business School | MBA | Former |
| Dartmouth College | B.A. | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes


